EDIT vs EMN · rev $32.3M vs P/E 21, rev $9.38B
Editas Medicine Inc (EDIT) versus Eastman Chemical Company (EMN) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Eastman Chemical Company (EMN) is a specialty chemicals company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported EMN revenue for 2024-12-31 was $9.38B. Net income was $908.0M. Revenue was up 1.9% from 2023-12-31 to 2024-12-31. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
EDIT currently screens at market cap $375.2M. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
Not investment advice. Open the EDIT and EMN stock pages for the full models.
Not investment advice.